Sign in to follow
Search Results

0 results for 'Saiber'

You can use to get even better search results
September 17, 2010 |

On The Move

Announcements about lawyers, firms and judges.
2 minute read
Generics Knock Out Eli Lilly ADHD Drug Patent
Publication Date: 2010-08-13
Practice Area:
Industry:
Court:
Judge:
Attorneys:
For plaintiff:
For defendant:
Case number:

"From the defense perspective, Eli Lilly was stuck between a rock and a hard place in this case," said Winston & Strawn partner James Hurst, who represented generic maker Sun Pharmaceuticals.

October 09, 2006 |

E-G

8 minute read
August 12, 2011 |

40 Under 40

The Law Journal's annual look at 40 promising young professionals in New Jersey's legal community, with biographies and photographs.
64 minute read
October 20, 2010 |

Largest Law Firms

86 minute read
September 24, 2012 |

Largest Law Firms

59 minute read
January 21, 2005 |

In re Mercedes-Benz Antitrust Litigation

Where defendants moved for summary judgment and plaintiffs moved to strike affidavits filed in support of the motion because of defendants' failure to disclose affiants' identities (an officer for the corporation and an expert), or that they had knowledge of issues in support of the motion, defendants were required to disclose the identify of the officer but not the expert, and such failure was not harmless or justified; although the affidavit is not excluded, plaintiffs are given opportunity to depose him.
11 minute read
April 24, 2006 |

Developer Wins $2.94M Verdict in Suit Over Land Condemned by N.J.

Large settlements and verdicts in New Jersey.
4 minute read
December 08, 2003 |

On the Move

Announcements about lawyers, firms and judges
2 minute read
October 11, 2004 |

Aventis Pharmaceuticals Inc. et al v. Barr Laboratories Inc. et al

The prosecution history of defendants' patents shows narrowing amendments made for reasons of patentability and, therefore, plaintiffs are barred from using the doctrine of equivalents in these infringement actions; also, by disclosing but not claiming certain inert ingredients, the patents have dedicated these ingredients to the public, and plaintiffs cannot now reclaim these through the doctrine of equivalents.
17 minute read

TRENDING STORIES

    More from ALM

    More from ALM

    Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

    Resources